Amicus Therapeutics, Inc.
Σύμβολο: FOLD
NASDAQ
10.4
USDΤιμή αγοράς σήμερα
-20.1432
Λόγος P/E
-0.2119
Δείκτης PEG
3.08B
MRK Cap
- 0.00%
DIV Απόδοση
Amicus Therapeutics, Inc. (FOLD) Οικονομικές καταστάσεις
Ισολογισμός
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1099.23 | 286.2 | 293.6 | 482.5 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 217.01 | 39.2 | 144.8 | 237.3 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 292.86 | 87.6 | 66.2 | 52.7 | ||||||||||||||||||||
balance-sheet.row.inventory | 195.02 | 59.7 | 23.8 | 26.8 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 191.73 | 49.5 | 40.2 | 34.8 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 1778.84 | 483.1 | 423.8 | 596.8 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 236.73 | 58 | 60.3 | 63.1 | ||||||||||||||||||||
balance-sheet.row.goodwill | 791.19 | 197.8 | 197.8 | 197.8 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 86.92 | 20.5 | 23 | 23 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 878.11 | 218.3 | 220.8 | 220.8 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 13.44 | 3.1 | 4.3 | -4.9 | ||||||||||||||||||||
balance-sheet.row.tax-assets | -10.36 | 0 | 4.9 | 4.9 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 75.82 | 15.5 | 10 | 24.4 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 1193.74 | 294.8 | 300.4 | 308.3 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 2972.58 | 777.9 | 724.2 | 905.1 | ||||||||||||||||||||
balance-sheet.row.account-payables | 76.76 | 15.1 | 15.4 | 21.5 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 31.93 | 8.3 | 8.6 | 7.4 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 12.43 | 12.4 | 5.9 | 6.2 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 1722.72 | 387.9 | 443.6 | 432.7 | ||||||||||||||||||||
Deferred Revenue Non Current | 17.72 | 0 | 4.7 | 7.3 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -17.72 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 513.63 | 131.8 | 110.1 | 117.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1830.25 | 450 | 462.1 | 451.8 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 227.27 | 48.9 | 60.1 | 50.8 | ||||||||||||||||||||
balance-sheet.row.total-liab | 2465.01 | 617.7 | 601.1 | 597.8 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 6.77 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 11.48 | 2.9 | 2.8 | 2.8 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | -10548.38 | -2684.1 | -2532.5 | -2295.9 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -4.04 | 5.3 | -12.1 | 5 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 11041.73 | 2836 | 2664.8 | 2595.5 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 507.56 | 160.2 | 123 | 307.4 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 2972.58 | 777.9 | 724.2 | 905.1 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-equity | 507.56 | 160.2 | 123 | 307.4 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 2972.58 | - | - | - | ||||||||||||||||||||
Total Investments | 220.09 | 42.3 | 144.8 | 237.3 | ||||||||||||||||||||
balance-sheet.row.total-debt | 1803.53 | 445.1 | 452.1 | 440.1 | ||||||||||||||||||||
balance-sheet.row.net-debt | 921.3 | 198.1 | 303.3 | 194.9 |
Κατάσταση ταμειακών ροών
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -151.58 | -151.6 | -236.6 | -250.5 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 7.87 | 7.9 | 5.3 | 6.2 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | -9.97 | -4.9 | 0 | 0 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 86.08 | 86.1 | 76.5 | 57.8 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | -40.05 | -48 | -39.9 | -18.6 | |||||||||||||||||||
cash-flows.row.account-receivables | -20.11 | -20.1 | -17.3 | -8.2 | |||||||||||||||||||
cash-flows.row.inventory | -44.61 | -44.6 | -5.3 | -7.8 | |||||||||||||||||||
cash-flows.row.account-payables | 49.19 | 49.2 | -6.4 | 7.4 | |||||||||||||||||||
cash-flows.row.other-working-capital | -24.53 | -32.5 | -10.8 | -10 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | 38.57 | 41.5 | 28 | 2.5 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -69.09 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -7.44 | -7.4 | -3.8 | -3.9 | |||||||||||||||||||
cash-flows.row.acquisitions-net | -12.2 | 0 | 3.4 | 3.9 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -91.72 | -91.7 | -243.3 | -341.4 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 197.23 | 197.2 | 335.9 | 424 | |||||||||||||||||||
cash-flows.row.other-investing-activites | 12.2 | 0 | 0 | -3.9 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 98.06 | 98.1 | 92.3 | 78.8 | |||||||||||||||||||
cash-flows.row.debt-repayment | -20.96 | -21 | -0.3 | -0.5 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 95.35 | 103.2 | 4.3 | 199.8 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | -17.92 | 0 | -11.5 | -15 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -4.3 | -15 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 7.19 | -20.6 | 4.3 | 42.8 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 61.68 | 61.7 | -7.5 | 212.1 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 6.31 | 6.3 | -14.6 | -5 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 96.83 | 98.2 | -96.3 | 83.3 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 892.58 | 247 | 153.1 | 249.5 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 795.75 | 148.8 | 249.5 | 166.2 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | -69.09 | -69.1 | -166.6 | -202.5 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -7.44 | -7.4 | -3.8 | -3.9 | |||||||||||||||||||
cash-flows.row.free-cash-flow | -76.53 | -76.5 | -170.3 | -206.4 |
Σειρά κατάστασης λογαριασμού αποτελεσμάτων
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 399.36 | 399.4 | 329.2 | 305.5 | |||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 39.51 | 45.2 | 38.6 | 34.5 | |||||||||||||||||||||
income-statement-row.row.gross-profit | 359.85 | 354.2 | 290.6 | 271 | |||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||
income-statement-row.row.research-development | 152.38 | - | - | - | |||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||||
income-statement-row.row.other-expenses | -8.69 | -15.9 | 5.3 | 6.2 | |||||||||||||||||||||
income-statement-row.row.operating-expenses | 431.11 | 427.7 | 495.1 | 471 | |||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 470.62 | 472.9 | 533.7 | 505.4 | |||||||||||||||||||||
income-statement-row.row.interest-income | 7.08 | 7.1 | 3 | 0.5 | |||||||||||||||||||||
income-statement-row.row.interest-expense | 24.18 | 50.1 | 37.1 | 32.5 | |||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -63.86 | -76.6 | -37.6 | -41.6 | |||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -8.69 | -15.9 | 5.3 | 6.2 | |||||||||||||||||||||
income-statement-row.row.total-operating-expenses | -63.86 | -76.6 | -37.6 | -41.6 | |||||||||||||||||||||
income-statement-row.row.interest-expense | 24.18 | 50.1 | 37.1 | 32.5 | |||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 4.13 | 7.9 | 12.5 | 3.8 | |||||||||||||||||||||
income-statement-row.row.ebitda-caps | -94.93 | - | - | - | |||||||||||||||||||||
income-statement-row.row.operating-income | -76.96 | -73.5 | -204.4 | -199.9 | |||||||||||||||||||||
income-statement-row.row.income-before-tax | -150.1 | -150.1 | -242 | -241.6 | |||||||||||||||||||||
income-statement-row.row.income-tax-expense | 7.74 | 1.5 | -5.5 | 8.9 | |||||||||||||||||||||
income-statement-row.row.net-income | -151.58 | -151.6 | -236.6 | -250.5 |
Συχνές ερωτήσεις
Ποιο είναι το Amicus Therapeutics, Inc. (FOLD) το σύνολο του ενεργητικού?
Amicus Therapeutics, Inc. (FOLD) το συνολικό ενεργητικό είναι 777880000.000.
Ποια είναι τα ετήσια έσοδα της επιχείρησης?
Τα ετήσια έσοδα είναι 218583000.000.
Ποιο είναι το περιθώριο κέρδους της επιχείρησης?
Το περιθώριο κέρδους της επιχείρησης είναι 0.901.
Ποια είναι η ελεύθερη ταμειακή ροή της επιχείρησης?
Η ελεύθερη ταμειακή ροή είναι -0.261.
Ποιο είναι το καθαρό περιθώριο κέρδους της επιχείρησης?
Το καθαρό περιθώριο κέρδους είναι -0.380.
Ποια είναι τα συνολικά έσοδα της επιχείρησης?
Τα συνολικά έσοδα είναι -0.193.
Ποια είναι η Amicus Therapeutics, Inc. (FOLD) καθαρό κέρδος (καθαρό εισόδημα)?
Το καθαρό κέρδος (καθαρό εισόδημα) είναι -151584000.000.
Ποιο είναι το συνολικό χρέος της επιχείρησης?
Το συνολικό χρέος είναι 445059000.000.
Ποιος είναι ο αριθμός των λειτουργικών εξόδων?
Τα λειτουργικά έξοδα είναι 427651000.000.
Ποιος είναι ο αριθμός των ταμειακών διαθεσίμων της εταιρείας?
Τα ταμειακά διαθέσιμα της επιχείρησης είναι 246994000.000.